Form 4: Addex Therapeutics CEO Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Timothy Mark Dyer, CHIEF EXECUTIVE OFFICER and a Director of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Summary

  • Disposition to the issuer: disposed of 16,413,787 Common Stock on September 2, 2026; holds 435,192 after (Direct).
  • Grant/award: acquired 16,413,787 Common Stock on September 2, 2026; holds 16,848,979 after (Direct).
  • Disposition to the issuer: disposed of 3,369,796 Stock-option (Right to Buy) on September 2, 2026 (Direct).
  • Grant/award: acquired 3,369,796 Stock-option (Right to Buy) on September 2, 2026; holds 3,369,796 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Timothy Mark Dyer — Director, Officer (CHIEF EXECUTIVE OFFICER)

DateTransactionSecuritySharesPriceValueHeld After
2026-09-02Disposition to the issuerCommon Stock16,413,787——435,192
2026-09-02Grant/awardCommon Stock16,413,787——16,848,979
2026-09-02Disposition to the issuerStock-option (Right to Buy)3,369,796——0
2026-09-02Grant/awardStock-option (Right to Buy)3,369,796——3,369,796

Key Dates

DateDescription
2026-09-02Disposition to the issuer (16,413,787 shares)
2026-09-02Grant/award (16,413,787 shares)
2026-09-02Disposition to the issuer (3,369,796 shares)
2026-09-02Grant/award (3,369,796 shares)

Keywords

insider transaction, Form 4, ADXN, Addex Therapeutics Ltd., neutral, Timothy Mark Dyer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.